$73.64 Million in Sales Expected for Collegium Pharmaceutical Inc (COLL) This Quarter
Wall Street brokerages predict that Collegium Pharmaceutical Inc (NASDAQ:COLL) will report sales of $73.64 million for the current quarter, Zacks Investment Research reports. Four analysts have issued estimates for Collegium Pharmaceutical’s earnings. The highest sales estimate is $76.25 million and the lowest is $70.86 million. Collegium Pharmaceutical posted sales of $10.79 million during the same quarter last year, which would indicate a positive year over year growth rate of 582.5%. The company is scheduled to report its next earnings results on Wednesday, March 6th.
According to Zacks, analysts expect that Collegium Pharmaceutical will report full-year sales of $280.30 million for the current fiscal year, with estimates ranging from $277.85 million to $283.24 million. For the next financial year, analysts anticipate that the firm will post sales of $310.43 million, with estimates ranging from $310.00 million to $311.16 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research firms that that provide coverage for Collegium Pharmaceutical.
Collegium Pharmaceutical (NASDAQ:COLL) last released its earnings results on Thursday, November 8th. The specialty pharmaceutical company reported ($0.50) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.36) by ($0.14). The business had revenue of $70.20 million for the quarter, compared to analysts’ expectations of $74.79 million. Collegium Pharmaceutical had a negative net margin of 30.13% and a negative return on equity of 70.06%. The company’s revenue was up 485.0% compared to the same quarter last year. During the same period last year, the firm earned ($0.45) EPS.
In other Collegium Pharmaceutical news, Director Michael Thomas Heffernan sold 25,000 shares of the stock in a transaction on Tuesday, January 15th. The stock was sold at an average price of $15.56, for a total transaction of $389,000.00. Following the sale, the director now owns 286,000 shares in the company, valued at $4,450,160. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In the last 90 days, insiders have sold 75,000 shares of company stock worth $1,258,500. Company insiders own 13.87% of the company’s stock.
Several large investors have recently bought and sold shares of COLL. Meeder Asset Management Inc. grew its stake in shares of Collegium Pharmaceutical by 644.8% in the fourth quarter. Meeder Asset Management Inc. now owns 3,672 shares of the specialty pharmaceutical company’s stock worth $62,000 after purchasing an additional 3,179 shares during the last quarter. Vanguard Group Inc lifted its holdings in Collegium Pharmaceutical by 9.0% in the third quarter. Vanguard Group Inc now owns 1,375,709 shares of the specialty pharmaceutical company’s stock worth $20,278,000 after buying an additional 113,038 shares during the period. Vanguard Group Inc. lifted its holdings in Collegium Pharmaceutical by 9.0% in the third quarter. Vanguard Group Inc. now owns 1,375,709 shares of the specialty pharmaceutical company’s stock worth $20,278,000 after buying an additional 113,038 shares during the period. Morgan Stanley lifted its holdings in Collegium Pharmaceutical by 20.1% in the third quarter. Morgan Stanley now owns 1,056,133 shares of the specialty pharmaceutical company’s stock worth $15,566,000 after buying an additional 176,577 shares during the period. Finally, Teachers Advisors LLC lifted its holdings in Collegium Pharmaceutical by 6.2% in the third quarter. Teachers Advisors LLC now owns 77,036 shares of the specialty pharmaceutical company’s stock worth $1,136,000 after buying an additional 4,484 shares during the period.
Shares of NASDAQ COLL traded down $0.24 during trading hours on Friday, hitting $15.08. The stock had a trading volume of 15,617 shares, compared to its average volume of 421,372. The stock has a market cap of $523.98 million, a price-to-earnings ratio of -6.11 and a beta of 0.52. Collegium Pharmaceutical has a 52 week low of $13.70 and a 52 week high of $29.90. The company has a debt-to-equity ratio of 4.17, a quick ratio of 0.75 and a current ratio of 0.78.
Collegium Pharmaceutical Company Profile
Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and tampering, including chewing, crushing, and/or dissolving.
See Also: Do You Need a Fiduciary?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.